PRESSEPORTAL Presseportal Logo

plus de sujets

Tous Actualités
Suivre
Abonner Zeltia Group
Pourquoi dois-je entrer mon adresse électronique ?

Zeltia Group

Zeltia Group: Report at 31 March 2005

Madrid (ots/PRNewswire)

PharmaMar:
  • Zalypsis: this is PharmaMar's fifth compound to reach clinical development.
  • Aplidin: commenced Phase II studies on prostate and bladder cancer.
  • Yondelis: pivotal Phase III studies commenced on ovarian cancer patients.
NeuroPharma:
- Presented pre-clinical data at the 7th International Conference
on Alzheimer's and Parkinson's Disease.
Other:
  • Investment in R&D amounted to 8.9 million euro in the first quarter.
  • Group short- and long-term debt was similar to December 2004.
  • Net cash consumption was 3.8 million euro in the first quarter.

Contact:

Isabel Lozano, CEO, PHARMAMAR, S.A., C/ Reyes, 1.Colmenar Viejo,
Madrid, Telephone +34-91-846-60-00; Catherine Moukheibir, Head of
Capital Market Strategy, ZELTIA, S.A., José Abascal, 2. Madrid,
Telephone +34-91-444-45-00; Ma. Luisa de Francia, CFO, ZELTIA, S.A.,
José Abascal, 2. Madrid, Telephone +34-91-444-45-00

Tous Actualités
Suivre
Abonner Zeltia Group
Pourquoi dois-je entrer mon adresse électronique ?
  • Version imprimable
  • Version PDF
Sujets abordés dans ce communiqué
Plus de actualités: Zeltia Group
Plus de actualités: Zeltia Group
Tous Actualités Tous
  • 18.04.2005 – 08:37

    PharmaMar Presents 13 Posters at AACR Highlighting Clinical and Preclinical Development Pipeline

    Anaheim, California (ots/PRNewswire) - PharmaMar today announces the presentation of thirteen posters highlighting advances with its clinical and preclinical compounds at the 96th Annual Meeting of the American Association for Cancer Research (AACR), taking place in Anaheim, California from 16-20 April 2005. The posters include results from research on Yondelis(R), ...

    plus
  • 24.02.2005 – 08:15

    Zeltia: Report at 31 December 2004

    Madrid, Spain (ots/PRNewswire) - PharmaMar: - Yondelis: - Due to the good results presented at the ASCO (American Society of Clinical Oncology) meeting, the randomised pivotal trial on soft-tissue sarcoma was expanded so as to compile a dossier for a regulatory application. - Results presented on ovarian cancer formed the basis for preparing Phase III trials in combination with Doxil. - The FDA (Food and Drug Administration) granted orphan ...

    plus
  • 17.02.2005 – 09:26

    Aplidin(R) Commences Phase II Clinical Trials in Prostate and Bladder Cancers

    Madrid, Spain (ots/PRNewswire) - PharmaMar announces that its second most advanced marine-derived anti-tumour agent, Aplidin(R), has commenced Phase II clinical trials in both prostate and bladder cancers. Phase II trial in Prostate Cancer This is the first trial of Aplidin in solid tumours to be carried out in the United States (US). This study will focus ...

    plus
Ces informations peuvent également vous intéresser
Ces informations peuvent également vous intéresser